Latest News
Operationalizing the scope of the Medicare drug negotiations
The Inflation Reduction Act of 2022 allowed Medicare to directly negotiate the prices of certain high-expenditure, single-source drugs without generic or biosimilar competition. The first set of negotiated prices will take effect in 2026. The Centers for Medicare and Medicaid Services has announced the second set of drugs selected for the negotiation program. Rachel Sachs and Richard G. Frank for Brookings analyzed the expansion of the Medicare drug price negotiation program. Read their analysis here…
This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.